Communication to the Editor : Analysis of an Impurity, N-Nitrosodimethylamine, in Valsartan Drug Substances and Associated Products Using GC-MS
-
- Tsutsumi Tomoaki
- National Institute of Health Sciences
-
- Akiyama Hiroshi
- National Institute of Health Sciences
-
- Demizu Yosuke
- National Institute of Health Sciences
-
- Uchiyama Nahoko
- National Institute of Health Sciences
-
- Masada Sayaka
- National Institute of Health Sciences
-
- Tsuji Genichiro
- National Institute of Health Sciences
-
- Arai Ryoko
- National Institute of Health Sciences
-
- Abe Yasuhiro
- National Institute of Health Sciences
-
- Hakamatsuka Takashi
- National Institute of Health Sciences
-
- Izutsu Ken-ichi
- National Institute of Health Sciences
-
- Goda Yukihiro
- National Institute of Health Sciences
-
- Okuda Haruhiro
- National Institute of Health Sciences
書誌事項
- タイトル別名
-
- Analysis of an Impurity, <i>N</i>-Nitrosodimethylamine, in Valsartan Drug Substances and Associated Products Using GC-MS
この論文をさがす
抄録
<p>Valsartan products, commonly used to treat high blood pressure and heart failure, have been recalled in many countries due to the presence of an impurity, N-nitrosodimethylamine (NDMA), in the recalled products. We present and evaluate a GC-MS-based analytical method for the determination of NDMA levels and attempt an investigation of NDMA concentrations in valsartan drug substances and associated products. The limit of detection and limit of quantification for the method were estimated to be 0.1 and 0.5 µg/g, respectively, when testing a 0.5-g sample. A good trueness (99%) with a small relative standard deviation (1.9%) was obtained for a valsartan product spiked with NDMA at a concentration of 1.0 µg/g. Additionally, a valsartan drug substance and the associated product, which were previously determined to have NDMA contamination, were analyzed by the method. The NDMA content by our method was very close to previously determined values. Finally, six samples, including valsartan drug substances and associated, commercially available products in Japan, all of which were derived from the company implicated in the NDMA contamination, were analyzed by our method, revealing that none of these samples contained detectable concentrations of NDMA. Overall, the data indicate that the present method is reliable and useful for determination of NDMA in valsartan drug substances and associated products.</p>
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 42 (4), 547-551, 2019-04-01
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282763120590848
-
- NII論文ID
- 130007622070
-
- NII書誌ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 029603992
-
- PubMed
- 30726781
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可